Researchers at the Perelman School of Medicine at the University of Pennsylvania have for the first time used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...

A new study identifies an extreme but effective way that brain immune cells can prevent the parasite Toxoplasma gondii from spreading: they kill themselves to eliminate the dangerous microbes they ...

Lipid nanoparticle (LNP) mRNA vaccines induce robust immune responses and provide protection against infectious diseases. However, this immunity can be short-lived, resulting in the need for frequent ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue ...

Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma. Treatment with cemacabtagene ansegedleucel (cema-cel) ...